Oct. 25 at 5:48 AM
$CLNN
December? I'm ba patient man, but let's talk about November, anyways. Now, then, according to GOOGLE:
"By acting as a surrogate endpoint for clinical benefit, NfL data can speed up the drug development process. For rare diseases (like ALS) with limited treatment options, regulatory agencies like the FDA may approve a drug based on strong NfL data alone, with confirmatory trials to follow."